Receptor News and Research

RSS

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.

10 May 2021

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC) and the University of Washington School of Medicine’s Institute for Protein Design (IPD) developed a universal flu vaccine candidate using small particles (nanoparticles), which can induce a long-lasting immune response.

10 May 2021

Is COVID-19 a new disease?

In a review recently published in The Lancet Respiratory Medicine journal by Osuchowski et al. (May 6th, 2021) the currently known pathophysiology of COVID-19 is laid out to describe the mechanistic features that make COVID-19 distinct from many conditions previously thought to be similar.

9 May 2021

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.

8 May 2021

Compound from tropical ginger plant can help in the treatment of inflammatory diseases

Many natural compounds have various anti-inflammatory and other beneficial properties that humans have been utilizing for medicinal purposes for hundreds of years.

7 May 2021

How did SARS-CoV-2 first evolve in humans?

In a perspective article recently published in the journal Science, Hyeryun Choe and Michael Farzan from the Scripps Research Institute, USA, have described the early-stage evolution of SARS-CoV-2 in humans. They have provided a detailed overview of how early mutations in SARS-CoV-2 spike protein facilitate its adaptation in human systems.

7 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Are infants at greater risk of COVID-19 than children?

The widely circulating SARS-CoV-2 has caused the devastating COVID-19 pandemic. The impact of this infection varies significantly with age, sparing young children for the most part, though not completely. However, a new study, released as a preprint on the medRxiv* server, shows that infants are not as resistant to the virus as children are. The researchers trace this to the expression of ACE2 to varying extents in different groups.

7 May 2021

Novel biomarker discovered to identify male COVID-19 patients at greatest risk for ICU admission

Researchers have discovered a novel biomarker to identify male COVID-19 patients most at risk for ICU admission.

7 May 2021

Researchers discover new binding sites for active agents on cell cytoskeleton

Through a unique combination of computer simulations and laboratory experiments, researchers at the Paul Scherrer Institute PSI have discovered new binding sites for active agents - against cancer, for example - on a vital protein of the cell cytoskeleton. Eleven of the sites hadn't been known before. The study appears today in the journal Angewandte Chemie International Edition.

7 May 2021

New transport system delivers large protein-based drugs into cancer cells

The ability of antibodies to recognize specific cancer cells is used in oncology to specifically target those cells with small active agents.

7 May 2021

Cryptic pocket on the surface of SARS-CoV-2 may be a promising treatment target

In a new study currently available on the bioRxiv* preprint server, a multinational group of researchers modeled an entire membrane-embedded spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlighted the potential of a specific mapping approach for unveiling cryptic, potentially druggable pockets on the viral surface.

7 May 2021

New strategy could increase the effectiveness of chemotherapy treatments

New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors' intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.

7 May 2021

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion

A study conducted by researchers in Germany has found that the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in India entered certain types of lung and intestine cells with slightly increased efficiency compared with the original wild-type strain.

6 May 2021

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

MUSC Hollings Cancer Center researchers added to the understanding of the protective immune response against the SARS-CoV-2 virus in a study published in April in iScience.

6 May 2021

SARS-CoV-2 is activated for fusion by a broad range of proteases, finds study

A team of researchers from the University of Virginia, USA, used single-virus fusion experiments with exogenously controlled proteases to investigate the mechanism of activation directly. They found that the subcellular location of entry depends on the protease activity of the various components, and parallel pathways are possible.

6 May 2021

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Transplant patients are typically on chronic immunosuppression, making them automatically more vulnerable to infection with SARS-CoV-2, the agent responsible for the loss of over three million lives in the current COVID-19 pandemic. A new study discusses evidence for subnormal immune responses following COVID-19 in this population.

6 May 2021

Could stem cells improve the outcome of ARDS in severe COVID-19?

A recent study, published in Stem Cells Translational Medicine, explores the safety and efficacy of stem cells, which have been touted as the panacea for a wide range of illnesses, ranging from chronic degenerative conditions to cancer.

6 May 2021

About 84% of antibodies in plasma target non-RBD epitopes on SARS-CoV-2 spike protein, finds study

In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.

6 May 2021

Receptor News and Research

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

Is COVID-19 a new disease?

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

Compound from tropical ginger plant can help in the treatment of inflammatory diseases

How did SARS-CoV-2 first evolve in humans?

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Are infants at greater risk of COVID-19 than children?

Novel biomarker discovered to identify male COVID-19 patients at greatest risk for ICU admission

Researchers discover new binding sites for active agents on cell cytoskeleton

New transport system delivers large protein-based drugs into cancer cells

Cryptic pocket on the surface of SARS-CoV-2 may be a promising treatment target

New strategy could increase the effectiveness of chemotherapy treatments

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

SARS-CoV-2 is activated for fusion by a broad range of proteases, finds study

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Could stem cells improve the outcome of ARDS in severe COVID-19?

About 84% of antibodies in plasma target non-RBD epitopes on SARS-CoV-2 spike protein, finds study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News